Collegium Pharmaceutical, Inc. (COLL)
Stock Price:
$18.25 USD
0.25 (1.36%)
Updated Oct 29, 2020 3:13 PM EDT - Market open
Key Info
| Market Cap |
629.92M |
| Revenue (ttm) |
301.71M |
| Net Income (ttm) |
198,000 |
| Shares Out |
34.53M |
| EPS (ttm) |
0.00 |
| PE Ratio |
n/a |
| Forward PE |
5.30 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 29, 2020 |
| Last Price |
$18.25 |
| Previous Close |
$18.00 |
| Change ($) |
0.25 |
| Change (%) |
1.36% |
| Day's Open |
18.10 |
| Day's Range |
17.71 - 18.54 |
| Day's Volume |
167,529 |
| 52-Week Range |
11.52 - 25.59 |
More Stats
| Market Cap |
629.92M |
| Enterprise Value |
768.45M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
34.53M |
| Float |
32.73M |
| EPS (basic) |
n/a |
| EPS (diluted) |
0.00 |
| FCF / Share |
-9.11 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.38M |
| Short Ratio |
14.73 |
| Short % of Float |
13.38% |
| Beta |
1.00 |
| PE Ratio |
n/a |
| Forward PE |
5.30 |
| P/FCF Ratio |
n/a |
| PS Ratio |
2.09 |
| PB Ratio |
4.29 |
| Revenue |
301.71M |
| Operating Income |
12.86M |
| Net Income |
198,000 |
| Free Cash Flow |
-313.22M |
| Net Cash |
-138.53M |
| Net Cash / Share |
-4.01 |
| Gross Margin |
34.15% |
| Operating Margin |
4.26% |
| Profit Margin |
0.10% |
| FCF Margin |
-103.81% |
| ROA |
1.70% |
| ROE |
0.16% |
| ROIC |
26.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (10)
| Buy |
8 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$27.38*
(50.07% upside)
Low
8.00
Current: $18.25
High
35.00
Target: 27.38
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 297 | 280 | 28.48 | 1.71 | - | - | - |
| Revenue Growth | 5.81% | 884.73% | 1564.29% | - | - | - | - |
| Gross Profit | 103 | 115 | 25.88 | 1.50 | - | - | - |
| Operating Income | -23.75 | -20.69 | -75.45 | -94.08 | -26.91 | -17.67 | -16.04 |
| Net Income | -22.72 | -39.13 | -74.87 | -94.18 | -27.26 | -17.92 | -16.20 |
| Shares Outstanding | 33.45 | 32.95 | 30.27 | 24.26 | 13.54 | 0.93 | 1.70 |
| Earnings Per Share | -0.68 | -1.19 | -2.47 | -3.88 | -1.48 | -22.72 | -4.06 |
| Operating Cash Flow | 27.78 | 169 | -67.02 | -75.05 | -21.57 | -17.95 | -16.53 |
| Capital Expenditures | -6.44 | -5.48 | -0.99 | -0.48 | -0.36 | -0.01 | -0.21 |
| Free Cash Flow | 21.35 | 164 | -68.01 | -75.53 | -21.93 | -17.96 | -16.74 |
| Cash & Equivalents | 170 | 147 | 119 | 153 | 95.79 | 1.71 | 7.63 |
| Total Debt | 21.59 | 11.50 | 1.48 | 4.15 | 6.81 | 13.07 | 1.03 |
| Net Cash / Debt | 148 | 135 | 117 | 149 | 88.98 | -11.35 | 6.60 |
| Assets | 306 | 291 | 136 | 162 | 97.72 | 5.09 | 9.03 |
| Liabilities | 219 | 200 | 31.49 | 27.11 | 12.65 | 17.33 | 3.45 |
| Book Value | 87.43 | 91.59 | 104 | 135 | 85.07 | -89.35 | -68.23 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Collegium Pharmaceutical, Inc. |
| Country |
United States |
| Employees |
255 |
| CEO |
Joseph J. Ciaffoni |
Stock Information
| Ticker Symbol |
COLL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: COLL |
| IPO Date |
May 7, 2015 |
Description
Collegium Pharmaceutical, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting. The company also offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. In addition, it offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.